SCHEMBL4262147

SCHEMBL4262147

Cc1cc(NC2CCC(N)CC2)nc(N(C)C)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN2 Q9H2S1 1/20 0.42
KCNN3 Q9UGI6 1/20 0.42
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
DNM2 P50570 1/20 0.38
CDK2 P24941 7/20 0.38
GSK3B P49841 6/20 0.38
CHEK1 O14757 1/20 0.38
CDK1 P06493 1/20 0.38
MAPKAPK2 P49137 3/20 0.37
CDK9 P50750 2/20 0.37
PIM1 P11309 2/20 0.37
CDC7 O00311 1/20 0.37
DAPK3 O43293 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4262141 1.00 KCNN2 (0.42) KCNN2KCNN3LMNAMEN1KMT2A
SCHEMBL4270930 0.82 PDGFRB (0.47) KCNN2KCNN3LMNAMEN1KMT2A
SCHEMBL4270924 0.82 PDGFRB (0.47) KCNN2KCNN3LMNAMEN1KMT2A
SCHEMBL4920620 0.82 CDK2 (0.38) KCNN2KCNN3LMNAMEN1KMT2A
SCHEMBL24512910 0.81 PTGS2 (0.43) CDK2GSK3BCHEK1CDK1MAPKAPK2
SCHEMBL24512912 0.81 PTGS2 (0.43) CDK2GSK3BCHEK1CDK1MAPKAPK2
SCHEMBL15830005 0.79 HRH3 (0.39) KCNN2KCNN3LMNAMEN1KMT2A
SCHEMBL15833940 0.79 KCNN2 (0.38) KCNN2KCNN3LMNAMEN1KMT2A
SCHEMBL4262384 0.77 CDK2 (0.38) CDK2GSK3BCHEK1CDK1MAPKAPK2
SCHEMBL4263812 0.77 CDK2 (0.38) CDK2GSK3BCHEK1CDK1MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090036448-A1 PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMECUTICAL CO., LTD. (JP) 2009-02-05 US disclosed
EP-1730122-A2 PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO., LTD (JP) 2006-12-13 EP disclosed
WO-2005095357-A2 PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO., LTD. (JP) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036448-A1 PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF GPR119, HCRTR2, MCHR1 KCNN2 2830/4885KCNN3 3574/4885LMNA 2888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.